Radiation therapy for low platelets from chemotherapy
Part of Cancer, Digestive system clinical trials.
This trial tests a treatment called selective internal radiation therapy (SIRT) to see if it can help raise platelet counts in people with gastrointestinal cancer whose spleen is enlarged due to chemotherapy. The treatment targets the spleen with tiny radioactive beads to reduce its activity, which may improve low blood platelet levels.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a confirmed gastrointestinal cancer (like stomach, pancreatic, or colorectal).
- Your spleen must be enlarged (seen on a CT scan) and your platelet count must be low (below 80,000) on two tests at least 7 days apart.
- You must be generally well enough that you can manage daily activities (ECOG score 0-2) and have a life expectancy of more than 6 months.
- You cannot have had a prior spleen removal or embolization, and you must not have a bleeding disorder unrelated to low platelets.
- If you could become pregnant, you must agree to use effective birth control during the study and for 3 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two medicines (Romiplostim N01 and ATRA) to raise dangerously low platelet counts that sometimes persist after chemotherapy for digestive cancers. If your platelets stay low even after previous platelet-raising treatments, this study may help.
This study tests a new medication called romiplostim that may help raise your platelet count when it drops too low after radiation therapy. If you have a solid tumor and your platelets are below 75,000, this treatment could help you recover and avoid complications.
This trial tests if hetrombopag can prevent low platelet counts caused by chemotherapy in people with gastrointestinal cancers. It may help reduce the risk of bleeding and the need for platelet transfusions.
This trial tests a new combination of two medicines (hetrombopag and rhTPO) that help raise platelet counts, which often drop during cancer treatment. The goal is to see if this approach works well and is safe for people with low platelets caused by cancer therapy.
This trial tests whether umbilical cord blood can help raise platelet levels in people whose platelets drop after cancer treatment. If it works, it might reduce the need for platelet transfusions and lower bleeding risk.
This trial tests a drug called romiplostim for patients whose platelet counts stay very low (below 30) for a long time after chemotherapy, even after other treatments have failed. The goal is to see if romiplostim can help raise your platelet count to a safer level.
Hear when a new Gastrointestinal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.